Claims
- 1. A biologically active agent isolated from Type 1 human female breast cyst fluid, having anti-hypertensive activity in mammals and having the properties of stimulating the enzyme Na.sup.+ K.sup.+ -ATPase and stimulating the binding of ouagain to its cellular receptor, wherein said agent is soluble in lower alcohols, absorbs light at 210 nm, is immunoreactive with antibodies to digoxin and is free of estradiol-sulfate or DHEA-sulfate.
- 2. The agent of claim 1 wherein said agent is isolated from Type 1 human female breast cyst fluid by
- agitating said Type 1 human female breast cyst fluid with a lower alcohol, thereby causing precipitation of undesirable constituents in said fluid,
- discarding the precipitate,
- mixing the alcohol-solubilized agent with a first polar solvent to form a second precipitate,
- discarding the second precipitate,
- evaporating said first polar solvent and recovering a first aqueous phase containing said agent,
- further extracting said first aqueous phase with a second polar solvent, said second polar solvent being less polar than said first polar solvent,
- obtaining an organic phase containing said agent,
- removing said second polar solvent from said organic phase and obtaining a second aqueous phase containing said agent,
- lyophilizing said second aqueous phase,
- extracting said lyophilizate with methanol-water,
- subjecting said extract to chromatography on pressure stabilized polydextran, and
- recovering said agent.
- 3. A pharamceutical formulation comprising a biologically active agent isolated from Type 1 human female breast cyst fluid, having antihypertensive activity in mammals and having the properties of stimulating the enzyme Na.sup.+ K.sup.+ -ATPase and stimulating the binding of ouabain to its cellular receptor, wherein said agent is soluble in lower alcohols, absorbs light at 210 nm, is immunoreactive with antibodies to digoxin and is free of estradiol-sulfate or DHEA-sulfate in combination with pharmaceutically acceptable carriers or salts.
- 4. The pharamceutical formulation of claim 3 comprising between about 10 ng digoxin equivalents and about 1000 ng digoxin equivalents of said agent.
- 5. The pharmaceutical formulation of claim 4 wherein said dosage form is an oral dosage form selected from the group consisting of a tablet and a capsule.
- 6. The pharmaceutical of claim 3 comprising a parenteral dosage form.
- 7. A pharmaceutical formulation comprising an aqueous solution of a biologically active agent isolated from Type 1 human female breast cyst fluid, having antihypertensive activity in mammals and having the properties of stimulating the enzyme Na.sup.+ K.sup.+ - ATPas and stimulating the binding of ouabain to its cellular receptor, wherein said agent is soluble in lower alcohols, absorbs light at 210 nm, is immunoreactive with antibodies to digoxin and is free of estradiolsulfate or DHEA-sulfate.
- 8. The agent of claim 2 wherein said agent is further purified using an amino carbohydrate column.
FIELD OF THE INVENTION
This application is a continuation of application Ser. No. 130,805, filed Dec. 9, 1987 now U.S. Pat. No. 5,028,438 which is a continuation-in-part of U.S. patent application Ser. No. 939,552, filed Dec. 9, 1986 now abandoned.
US Referenced Citations (6)
Foreign Referenced Citations (6)
Number |
Date |
Country |
0407348 |
May 1968 |
AUX |
2707164 |
Aug 1978 |
DEX |
53-133617 |
Nov 1978 |
JPX |
60-28987 |
Feb 1985 |
JPX |
0741882 |
Jul 1980 |
SUX |
1186624 |
Apr 1970 |
GBX |
Non-Patent Literature Citations (5)
Entry |
Goodman and Gilman's The Pharmacological Basis of Therapeutics 6th Ed. pp. 730,753,936-937 1980. |
Raju et al; J. Endocrinol. Metab. 45(3):429-434 (1977). |
Raju et al; J. Steroid Biochem 20(4B): 1061-1065 (1984). |
Raju et al; J. Clin. Endocrinol. Metab. 60(5): 940-946 (1985). |
Raju et al; Steroids 45(3-4): 341-346 (1985). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
130805 |
Dec 1987 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
939552 |
Dec 1986 |
|